Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?

Savara Inc. SVRA on Tuesday announced that it received a U.S. Food And Drug Administration (FDA) refusal To File (RTF)) letter regarding the Biologic license application (BLA) for Molbreevi, a therapy for treating patients with autoimmune Pulmonary Alveolar Proteinosis (PAP).Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the lungs’ alveoli.Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent th ...